APLS
Price
$24.52
Change
+$0.37 (+1.53%)
Updated
Oct 17 closing price
Capitalization
3.1B
10 days until earnings call
Intraday Buy/Sell Signals
QNRX
Price
$14.89
Change
+$1.35 (+9.97%)
Updated
Oct 17 closing price
Capitalization
8.98M
Intraday Buy/Sell Signals
Interact to see
Advertisement

APLS vs QNRX

Header iconAPLS vs QNRX Comparison
Open Charts APLS vs QNRXBanner chart's image
Apellis Pharmaceuticals
Price$24.52
Change+$0.37 (+1.53%)
Volume$1.65M
Capitalization3.1B
Quoin Pharmaceuticals
Price$14.89
Change+$1.35 (+9.97%)
Volume$214.3K
Capitalization8.98M
APLS vs QNRX Comparison Chart in %
APLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
QNRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
APLS vs. QNRX commentary
Oct 20, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is APLS is a Hold and QNRX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 20, 2025
Stock price -- (APLS: $24.52 vs. QNRX: $14.89)
Brand notoriety: APLS and QNRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: APLS: 76% vs. QNRX: 53%
Market capitalization -- APLS: $3.1B vs. QNRX: $8.98M
APLS [@Biotechnology] is valued at $3.1B. QNRX’s [@Biotechnology] market capitalization is $8.98M. The market cap for tickers in the [@Biotechnology] industry ranges from $106.87B to $0. The average market capitalization across the [@Biotechnology] industry is $2.06B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

APLS’s FA Score shows that 0 FA rating(s) are green whileQNRX’s FA Score has 2 green FA rating(s).

  • APLS’s FA Score: 0 green, 5 red.
  • QNRX’s FA Score: 2 green, 3 red.
According to our system of comparison, QNRX is a better buy in the long-term than APLS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

APLS’s TA Score shows that 5 TA indicator(s) are bullish while QNRX’s TA Score has 7 bullish TA indicator(s).

  • APLS’s TA Score: 5 bullish, 6 bearish.
  • QNRX’s TA Score: 7 bullish, 3 bearish.
According to our system of comparison, QNRX is a better buy in the short-term than APLS.

Price Growth

APLS (@Biotechnology) experienced а -2.39% price change this week, while QNRX (@Biotechnology) price change was -27.37% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.56%. For the same industry, the average monthly price growth was +15.88%, and the average quarterly price growth was +79.09%.

Reported Earning Dates

APLS is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (+1.56% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
APLS($3.1B) has a higher market cap than QNRX($8.98M). APLS YTD gains are higher at: -23.159 vs. QNRX (-34.620). QNRX has higher annual earnings (EBITDA): -12.58M vs. APLS (-178.43M). APLS has more cash in the bank: 370M vs. QNRX (7.79M). QNRX has less debt than APLS: QNRX (6.21M) vs APLS (470M). APLS has higher revenues than QNRX: APLS (755M) vs QNRX (0).
APLSQNRXAPLS / QNRX
Capitalization3.1B8.98M34,476%
EBITDA-178.43M-12.58M1,418%
Gain YTD-23.159-34.62067%
P/E RatioN/A0.02-
Revenue755M0-
Total Cash370M7.79M4,750%
Total Debt470M6.21M7,565%
FUNDAMENTALS RATINGS
APLS vs QNRX: Fundamental Ratings
APLS
QNRX
OUTLOOK RATING
1..100
2898
VALUATION
overvalued / fair valued / undervalued
1..100
64
Fair valued
30
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
99100
PRICE GROWTH RATING
1..100
4536
P/E GROWTH RATING
1..100
1008
SEASONALITY SCORE
1..100
9050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

QNRX's Valuation (30) in the Biotechnology industry is somewhat better than the same rating for APLS (64) in the Medical Distributors industry. This means that QNRX’s stock grew somewhat faster than APLS’s over the last 12 months.

QNRX's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as APLS (100) in the Medical Distributors industry. This means that QNRX’s stock grew similarly to APLS’s over the last 12 months.

APLS's SMR Rating (99) in the Medical Distributors industry is in the same range as QNRX (100) in the Biotechnology industry. This means that APLS’s stock grew similarly to QNRX’s over the last 12 months.

QNRX's Price Growth Rating (36) in the Biotechnology industry is in the same range as APLS (45) in the Medical Distributors industry. This means that QNRX’s stock grew similarly to APLS’s over the last 12 months.

QNRX's P/E Growth Rating (8) in the Biotechnology industry is significantly better than the same rating for APLS (100) in the Medical Distributors industry. This means that QNRX’s stock grew significantly faster than APLS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
APLSQNRX
RSI
ODDS (%)
Bullish Trend 3 days ago
63%
Bearish Trend 3 days ago
89%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
88%
Bullish Trend 3 days ago
88%
Momentum
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 3 days ago
88%
MACD
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 3 days ago
76%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
80%
Bearish Trend 3 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 3 days ago
85%
Advances
ODDS (%)
Bullish Trend 13 days ago
81%
Bullish Trend 12 days ago
87%
Declines
ODDS (%)
Bearish Trend 6 days ago
80%
Bearish Trend 6 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
86%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bearish Trend 3 days ago
86%
Bullish Trend 3 days ago
77%
View a ticker or compare two or three
Interact to see
Advertisement
APLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
QNRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JSGAX30.810.15
+0.49%
JHancock U.S. Growth A
CSGTX4.13N/A
N/A
Transamerica Small Cap Growth C
IAXTX8.21-0.02
-0.24%
VY® T. Rowe Price Divers Mid Cap Gr S2
MGICX38.10-0.26
-0.68%
MFS International Intrinsic Value C
MISGX12.80-0.13
-1.01%
Meridian Small Cap Growth Investor

APLS and

Correlation & Price change

A.I.dvisor indicates that over the last year, APLS has been loosely correlated with DNLI. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if APLS jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To APLS
1D Price
Change %
APLS100%
+1.53%
DNLI - APLS
49%
Loosely correlated
-0.36%
ARWR - APLS
43%
Loosely correlated
-5.54%
DAWN - APLS
43%
Loosely correlated
-3.61%
DYN - APLS
42%
Loosely correlated
-0.24%
ROIV - APLS
41%
Loosely correlated
+0.88%
More